Unlike traditional drug discovery efforts that have focused exclusively on the human side of the equation, Second Genome is working on therapeutic product breakthroughs by uncovering how the microbiota interacts with itself and with its human host to impact health and disease.

For every one human gene we have, there are 100 associated genes within our microbiome. More than 100 trillion microorganisms live in our gut, mouth, skin and other mucosal surfaces of our bodies. These microbes have numerous beneficial functions relevant to supporting life such as digesting food, preventing disease-causing pathogens from invading the body, and synthesizing essential nutrients and vitamins. With the advancement of genomic technologies, the capacity of this second genome to influence health and disease can now be harnessed.

Published research makes clear that the human microbiome is a fundamental component of human physiology, with an estimated one-third of circulating metabolites being a product of the gut microbiota. Changes in the microbiome can trigger changes in human cellular activities, resulting in disease or contribute to its progression. The ability to understand these mechanisms and disease processes is central to the Second Genome drug discovery program. By gaining deep knowledge of the molecular mechanisms that govern the dynamic interplay between microbial communities and host system, we can unlock meaningful insights into the pathogenesis of disease, enabling rational strategies for therapeutic intervention.